NewsBenzingaCardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis Benzinga 2026.09.23 10:02 (GMT+0) Open on Benzinga Other news China's Central Bank: Do a Good Job in Financial Support for the Development of the AI Industry Peter Schiff Says AI Could Rewrite the Rules of Starting a Business: ‘Don’t Look for a Job’ Hunterbrook Report: Digital Realty’s $3 Billion Georgia Data Center Hits Toxic Roadblock After White Phosphorus Found At Former Army Dump Pre-market US stocks: Memory sector broadly higher, Micron Technology (MU.O) up 2.40% AbbVie’s Dual-Target Drug Shows Phase 2 Results for Hard-to-Treat Crohn’s Disease Musk announces he will gift one SpaceX share to every child in the U.S. next year
Hunterbrook Report: Digital Realty’s $3 Billion Georgia Data Center Hits Toxic Roadblock After White Phosphorus Found At Former Army Dump
